JPWO2022174813A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022174813A5 JPWO2022174813A5 JP2023550109A JP2023550109A JPWO2022174813A5 JP WO2022174813 A5 JPWO2022174813 A5 JP WO2022174813A5 JP 2023550109 A JP2023550109 A JP 2023550109A JP 2023550109 A JP2023550109 A JP 2023550109A JP WO2022174813 A5 JPWO2022174813 A5 JP WO2022174813A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- polypeptide chain
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims 81
- 229920001184 polypeptide Polymers 0.000 claims 80
- 102000004196 processed proteins & peptides Human genes 0.000 claims 80
- 239000000427 antigen Substances 0.000 claims 36
- 102000036639 antigens Human genes 0.000 claims 36
- 108091007433 antigens Proteins 0.000 claims 36
- 239000012634 fragment Substances 0.000 claims 18
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 8
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 6
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 6
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 6
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims 4
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108010075254 C-Peptide Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110189359 | 2021-02-19 | ||
| CN202110189359.8 | 2021-02-19 | ||
| PCT/CN2022/076832 WO2022174813A1 (zh) | 2021-02-19 | 2022-02-18 | 抗GPRC5DxBCMAxCD3三特异性抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510098A JP2024510098A (ja) | 2024-03-06 |
| JPWO2022174813A5 true JPWO2022174813A5 (enrdf_load_stackoverflow) | 2025-02-28 |
Family
ID=82932102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550109A Pending JP2024510098A (ja) | 2021-02-19 | 2022-02-18 | 抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用 |
Country Status (8)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021353368A1 (en) * | 2020-09-29 | 2023-05-25 | Fortvita Biologics (Singapore) Pte.Ltd. | Anti-cd3 antibody and uses thereof |
| IL317463A (en) * | 2022-06-06 | 2025-02-01 | Shandong Simcere Biopharmaceutical Co Ltd | Multispecific antibodies targeting BCMA, GPRC5D and T cells and their application |
| EP4585615A1 (en) * | 2022-09-09 | 2025-07-16 | Beijing Mabworks Biotech Co., Ltd | Multispecific antibody binding to bcma, gprc5d and cd3, and use thereof |
| CN117924485A (zh) * | 2022-10-25 | 2024-04-26 | 上海祥耀生物科技有限责任公司 | 一种抗gprc5d的多特异性抗体 |
| TW202434644A (zh) | 2023-02-07 | 2024-09-01 | 大陸商上海齊魯製藥研究中心有限公司 | 三特異性抗原結合分子及其應用 |
| TW202502826A (zh) * | 2023-06-06 | 2025-01-16 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｇｐｒｃ５ｄ／ｂｃｍａ／ｃｄ３三特異性抗體的製備及其用途 |
| TW202527983A (zh) * | 2023-09-13 | 2025-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種包含特異性結合ｇｐｒｃ５ｄ和ｃｄ３的雙特異性抗體的醫藥組成物 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025092742A1 (zh) * | 2023-10-30 | 2025-05-08 | 美国礼至生物医药股份有限公司 | 结合bcma的抗体以及包含其的多特异性抗体 |
| TW202523355A (zh) * | 2023-12-04 | 2025-06-16 | 大陸商山東先聲生物製藥有限公司 | 一種多特異性抗體之組成物及其製備方法及應用 |
| WO2025131077A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3多特异性抗体及用途 |
| WO2025134049A1 (en) * | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis |
| WO2025134050A1 (en) * | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma |
| CN117843788B (zh) * | 2024-01-09 | 2025-02-11 | 四川大学 | 一种抗gprc5d的抗体及其多特异性抗体和相关应用 |
| WO2025190400A1 (zh) * | 2024-03-15 | 2025-09-18 | 福佑泰生物制药公司 | 抗dll3抗体及其用途 |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| MX2011011925A (es) * | 2009-05-27 | 2011-12-06 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos. |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| EP3237449A2 (en) * | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
| KR101997241B1 (ko) * | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
| AU2017238172B2 (en) * | 2016-03-21 | 2024-06-27 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2017165681A1 (en) * | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
| RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| WO2019005637A2 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF |
| TWI829667B (zh) * | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| AU2019270623B2 (en) * | 2018-05-16 | 2023-09-07 | Janssen Biotech, Inc. | BCMA/CD3 and GPRDC5D/CD3 bispecific antibodies for use in cancer therapy |
| US20220195041A1 (en) * | 2019-05-07 | 2022-06-23 | Immunorizon Ltd. | Precursor tri-specific antibody constructs and methods of use thereof |
| CN112062851B (zh) * | 2019-06-11 | 2022-09-09 | 南京驯鹿医疗技术有限公司 | 靶向bcma嵌合抗原受体的抗体及其应用 |
-
2022
- 2022-02-18 JP JP2023550109A patent/JP2024510098A/ja active Pending
- 2022-02-18 TW TW111106048A patent/TWI830151B/zh active
- 2022-02-18 US US18/546,862 patent/US20250074996A1/en active Pending
- 2022-02-18 CN CN202280015788.6A patent/CN116897166A/zh active Pending
- 2022-02-18 CA CA3211407A patent/CA3211407A1/en active Pending
- 2022-02-18 EP EP22755586.9A patent/EP4296286A4/en active Pending
- 2022-02-18 WO PCT/CN2022/076832 patent/WO2022174813A1/zh not_active Ceased
- 2022-02-18 AU AU2022223152A patent/AU2022223152A1/en active Pending